G단백질 연결 수용체 패밀리 C그룹 5 멤버 D(GPRC5D) 표적치료 시장 보고서(2026년)

G protein-coupled receptor family C group 5 member D (GPRC5D) targeted therapies are precise treatments designed to specifically identify and attack cells expressing the GPRC5D protein, which is abundantly present on malignant plasma cells, particularly in multiple myeloma. They provide highly targeted cancer treatment that maximizes tumor destruction while minimizing damage to healthy tissues.

The primary types of G protein-coupled receptor family C group 5 member D (GPRC5D) targeted therapies include monoclonal antibodies, bispecific antibodies, chimeric antigen receptor (CAR-T) cell therapies, and other therapy types. Monoclonal antibodies are lab-engineered antibodies specifically designed to target GPRC5D proteins on cancer cells to suppress tumor growth and activate the immune response. These therapies are indicated for conditions such as multiple myeloma, solid tumors, and other medical indications. They incorporate technologies including precision medicine techniques, molecular targeted therapy, cancer immunotherapy platforms, and biopharmaceutical drug delivery systems. Administration occurs via intravenous, subcutaneous, and other delivery routes, and end users include hospitals, specialty clinics, research institutes, and other users.

Tariffs are impacting the GPRC5D targeted therapies market by increasing costs of imported biologic manufacturing equipment, laboratory reagents, diagnostic kits, and sterile packaging materials used in drug development and delivery. Pharmaceutical manufacturers in North America and Europe are most affected due to reliance on global supply chains for active ingredients and consumables, while Asia-Pacific faces higher production input costs. These tariffs are increasing development expenses and extending commercialization timelines. However, they are also encouraging localized biomanufacturing, regional clinical trial expansion, and domestic sourcing of critical biologic inputs.

The g protein-coupled receptor family c group 5 member d (gprc5d) targeted therapies market research report is one of a series of new reports from The Business Research Company that provides g protein-coupled receptor family c group 5 member d (gprc5d) targeted therapies market statistics, including g protein-coupled receptor family c group 5 member d (gprc5d) targeted therapies industry global market size, regional shares, competitors with a g protein-coupled receptor family c group 5 member d (gprc5d) targeted therapies market share, detailed g protein-coupled receptor family c group 5 member d (gprc5d) targeted therapies market segments, market trends and opportunities, and any further data you may need to thrive in the g protein-coupled receptor family c group 5 member d (gprc5d) targeted therapies industry. This g protein-coupled receptor family c group 5 member d (gprc5d) targeted therapies market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The g protein-coupled receptor family c group 5 member d (gprc5d) targeted therapies market size has grown exponentially in recent years. It will grow from $0.59 billion in 2025 to $0.78 billion in 2026 at a compound annual growth rate (CAGR) of 32.7%. The growth in the historic period can be attributed to advancements in targeted cancer therapy research, increasing prevalence of multiple myeloma cases, expansion of monoclonal antibody development programs, improvements in clinical trial infrastructure, rising investments in oncology drug discovery.

The g protein-coupled receptor family c group 5 member d (gprc5d) targeted therapies market size is expected to see exponential growth in the next few years. It will grow to $2.42 billion in 2030 at a compound annual growth rate (CAGR) of 32.9%. The growth in the forecast period can be attributed to increasing regulatory approvals for targeted biologics, rising demand for personalized cancer treatments, expansion of next-generation immunotherapy platforms, growing investments in precision medicine ecosystems, increasing adoption of biomarker-based therapy selection. Major trends in the forecast period include increasing development of bispecific antibody therapies, rising focus on gprc5d biomarker-driven patient selection, growing adoption of car-t cell platforms, expansion of precision oncology clinical pipelines, enhanced integration of companion diagnostics.

The increasing prevalence of myeloma is anticipated to drive the expansion of the GPRC5D-targeted therapies market in the coming years. Myeloma is a type of cancer affecting plasma cells in the bone marrow, which interferes with normal blood cell production and may lead to bone damage, anemia, and kidney complications. The rising incidence of myeloma is partly attributed to aging populations, as the likelihood of developing plasma cell disorders grows with age due to accumulated genetic mutations over time. GPRC5D-targeted therapies treat myeloma by attaching to the GPRC5D protein on malignant plasma cells, guiding the immune system-particularly T cells-to selectively eliminate these cancerous cells while largely sparing healthy cells. For example, in January 2026, the American Cancer Society, a US-based professional organization, projected that the United States would record roughly 36,000 new multiple myeloma cases, including 20,150 in men and 15,850 in women, with an estimated 10,850 deaths, comprising 5,780 men and 5,070 women. Consequently, the rising prevalence of myeloma is fueling growth in the GPRC5D-targeted therapies market.

Leading companies operating in the GPRC5D targeted therapies market are focusing on developing innovative solutions, such as bispecific T cell engagers, to enhance immune-mediated targeting of cancer cells and improve treatment efficacy. A bispecific T-cell engager (BiTE) is a type of immunotherapy molecule designed to connect T-cells directly to cancer cells by binding both simultaneously, activating the T-cells to destroy the targeted cancer cells. For example, in August 2023, Johnson & Johnson, a US-based healthcare company, received an approval from the European Commission of TALVEY (talquetamab), Janssen's bispecific antibody therapy targeting GPRC5D, for relapsed and refractory multiple myeloma (RRMM) in patients after at least three prior therapies. It is a first-in-class bispecific T-cell engager targeting GPRC5D on multiple myeloma cells and CD3 on T cells to treat relapsed/refractory multiple myeloma in heavily pretreated patients. Its key purpose is providing durable responses (ORR >70% in trials) after at least four prior therapies, with advantages including subcutaneous dosing, sustained quality-of-life benefits, and efficacy even post-bispecifics or CAR-T, filling an unmet need in late-line disease.

In May 2023, LaNova Medicines Ltd., a China-based clinical-stage biotechnology company, entered into a partnership with AstraZeneca Plc to advance the development of novel oncology therapies through joint clinical programs. Through this collaboration, AstraZeneca aims to obtain global rights to research, develop, and commercialize LM-305, a preclinical-stage GPRC5D-targeting antibody-drug conjugate (ADC) designed for the treatment of relapsed or refractory multiple myeloma. AstraZeneca Plc is a UK-based company focused on developing GPRC5D-targeted therapies for multiple myeloma.

Major companies operating in the g protein-coupled receptor family c group 5 member d (gprc5d) targeted therapies market are Johnson And Johnson, F. Hoffmann-La Roche AG., AbbVie Inc., Sanofi S.A., AstraZeneca plc, Bristol Myers Squibb Company, Genmab A/S, Genentech Inc., Simcere Zaiming Biotechnology Co. Ltd., Innovent Biologics Inc., Essen Biotech Co. Ltd., Nanjing IASO Biotechnology Co. Ltd., CARsgen Therapeutics Holdings Limited, Oricell Therapeutics Co. Ltd., Integral Molecular Inc., Overland Therapeutics Inc., Qilu Pharmaceutical Co. Ltd., Leads Biolabs Ltd., ShanghAI Yake Biotechnology Co. Ltd., Guangzhou Bio-gene Technology Co. Ltd.

North America was the largest region in the GPRC5D targeted therapies market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the g protein-coupled receptor family c group 5 member d (gprc5d) targeted therapies market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the g protein-coupled receptor family c group 5 member d (gprc5d) targeted therapies market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The G protein-coupled receptor family C group 5 member D (GPRC5D) targeted therapies market consists of revenues earned by entities by providing services such as clinical trial management, personalized therapy design, patient screening and biomarker testing, regulatory consulting, and post-marketing support. The market value includes the value of related goods sold by the service provider or included within the service offering. The G protein-coupled receptor family C group 5 member D (GPRC5D) targeted therapies market also includes sales of monoclonal antibodies, antibody drug conjugates, targeted small molecule drugs, receptor-specific inhibitors, injectable biologics, oral targeted therapeutics, infusion kits, diagnostic companion kits, laboratory reagents, and vials and prefilled syringes. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

G Protein-Coupled Receptor Family C Group 5 Member D (GPRC5D) Targeted Therapies Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses g protein-coupled receptor family c group 5 member d (gprc5d) targeted therapies market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
• Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on end user analysis.
• Benchmark performance against key competitors based on market share, innovation, and brand strength.
• Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
• Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for g protein-coupled receptor family c group 5 member d (gprc5d) targeted therapies ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The g protein-coupled receptor family c group 5 member d (gprc5d) targeted therapies market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
• The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
• The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
• The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
• The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
• The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
• Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.

Scope

• Markets Covered:1) By Therapy Type: Monoclonal Antibodies; Bispecific Antibodies; Chimeric Antigen Receptor (CAR-T) Cell Therapies; Other Therapy Types
• 2) By Indication: Multiple Myeloma; Solid Tumors; Other Indications
• 3) By Technology: Precision Medicine Approaches; Molecular Targeted Therapy; Cancer Immunotherapy Platforms; Biopharmaceutical Drug Delivery Systems
• 4) By Route Of Administration: Intravenous; Subcutaneous; Other Routes Of Administration
• 5) By End-User: Hospitals; Specialty Clinics; Research Institutes; Other End-Users
• Subsegments:
• 1) By Monoclonal Antibodies: Fully Human Monoclonal Antibodies; Humanized Monoclonal Antibodies; Chimeric Monoclonal Antibodies; Murine Monoclonal Antibodies
• 2) By Bispecific Antibodies: Dual Targeting Bispecific Antibodies; Cross Linking Bispecific Antibodies; Immune Cell Engaging Bispecific Antibodies; Cytotoxic Bispecific Antibodies
• 3) By Chimeric Antigen Receptor (CAR-T) Cell Therapies: Autologous Car T Cell Therapies; Allogeneic Car T Cell Therapies; Next Generation Car T Cell Therapies; Gene Edited Car T Cell Therapies
• 4) By Other Therapy Types: Targeted Small Molecule Drugs; Receptor Specific Inhibitors; Injectable Biologics; Oral Targeted Therapeutics
• Companies Mentioned: Johnson And Johnson; F. Hoffmann-La Roche AG.; AbbVie Inc.; Sanofi S.A.; AstraZeneca plc; Bristol Myers Squibb Company; Genmab A/S; Genentech Inc.; Simcere Zaiming Biotechnology Co. Ltd.; Innovent Biologics Inc.; Essen Biotech Co. Ltd.; Nanjing IASO Biotechnology Co. Ltd.; CARsgen Therapeutics Holdings Limited; Oricell Therapeutics Co. Ltd.; Integral Molecular Inc.; Overland Therapeutics Inc.; Qilu Pharmaceutical Co. Ltd.; Leads Biolabs Ltd.; ShanghAI Yake Biotechnology Co. Ltd.; Guangzhou Bio-gene Technology Co. Ltd.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time Series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: Word, PDF or Interactive Report
• + Excel Dashboard
• Added Benefits
• Bi-Annual Data Update
• Customisation
• Expert Consultant Support

Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.

Table of Contents

1. Executive Summary

• 1.1. Key Market Insights (2020-2035)
• 1.2. Visual Dashboard: Market Size, Growth Rate, Hotspots
• 1.3. Major Factors Driving the Market
• 1.4. Top Three Trends Shaping the Market

2. G Protein-Coupled Receptor Family C Group 5 Member D (GPRC5D) Targeted Therapies Market Characteristics

• 2.1. Market Definition & Scope
• 2.2. Market Segmentations
• 2.3. Overview of Key Products and Services
• 2.4. Global G Protein-Coupled Receptor Family C Group 5 Member D (GPRC5D) Targeted Therapies Market Attractiveness Scoring And Analysis
  • 2.4.1. Overview of Market Attractiveness Framework
  • 2.4.2. Quantitative Scoring Methodology
  • 2.4.3. Factor-Wise Evaluation
• Growth Potential Analysis, Competitive Dynamics Assessment, Strategic Fit Assessment And Risk Profile Evaluation
• 2.4.4. Market Attractiveness Scoring and Interpretation
• 2.4.5. Strategic Implications and Recommendations

3. G Protein-Coupled Receptor Family C Group 5 Member D (GPRC5D) Targeted Therapies Market Supply Chain Analysis

• 3.1. Overview of the Supply Chain and Ecosystem
• 3.2. List Of Key Raw Materials, Resources & Suppliers
• 3.3. List Of Major Distributors and Channel Partners
• 3.4. List Of Major End Users

4. Global G Protein-Coupled Receptor Family C Group 5 Member D (GPRC5D) Targeted Therapies Market Trends And Strategies

• 4.1. Key Technologies & Future Trends
  • 4.1.1 Biotechnology, Genomics & Precision Medicine
  • 4.1.2 Artificial Intelligence & Autonomous Intelligence
  • 4.1.3 Industry 4.0 & Intelligent Manufacturing
  • 4.1.4 Digitalization, Cloud, Big Data & Cybersecurity
  • 4.1.5 Fintech, Blockchain, Regtech & Digital Finance
• 4.2. Major Trends
  • 4.2.1 Increasing Development Of Bispecific Antibody Therapies
  • 4.2.2 Rising Focus On Gprc5D Biomarker-Driven Patient Selection
  • 4.2.3 Growing Adoption Of Car-T Cell Platforms
  • 4.2.4 Expansion Of Precision Oncology Clinical Pipelines
  • 4.2.5 Enhanced Integration Of Companion Diagnostics

5. G Protein-Coupled Receptor Family C Group 5 Member D (GPRC5D) Targeted Therapies Market Analysis Of End Use Industries

• 5.1 Hospitals
• 5.2 Specialty Oncology Clinics
• 5.3 Research Institutes
• 5.4 Pharmaceutical Companies
• 5.5 Biotechnology Companies

6. G Protein-Coupled Receptor Family C Group 5 Member D (GPRC5D) Targeted Therapies Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, Supply Chain Impact from Tariff War & Trade Protectionism, And Covid And Recovery On The Market

7. Global G Protein-Coupled Receptor Family C Group 5 Member D (GPRC5D) Targeted Therapies Strategic Analysis Framework, Current Market Size, Market Comparisons And Growth Rate Analysis

• 7.1. Global G Protein-Coupled Receptor Family C Group 5 Member D (GPRC5D) Targeted Therapies PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 7.2. Global G Protein-Coupled Receptor Family C Group 5 Member D (GPRC5D) Targeted Therapies Market Size, Comparisons And Growth Rate Analysis
• 7.3. Global G Protein-Coupled Receptor Family C Group 5 Member D (GPRC5D) Targeted Therapies Historic Market Size and Growth, 2020 - 2025, Value ($ Billion)
• 7.4. Global G Protein-Coupled Receptor Family C Group 5 Member D (GPRC5D) Targeted Therapies Forecast Market Size and Growth, 2025 - 2030, 2035F, Value ($ Billion)

8. Global G Protein-Coupled Receptor Family C Group 5 Member D (GPRC5D) Targeted Therapies Total Addressable Market (TAM) Analysis for the Market

• 8.1. Definition and Scope of Total Addressable Market (TAM)
• 8.2. Methodology and Assumptions
• 8.3. Global Total Addressable Market (TAM) Estimation
• 8.4. TAM vs. Current Market Size Analysis
• 8.5. Strategic Insights and Growth Opportunities from TAM Analysis

9. G Protein-Coupled Receptor Family C Group 5 Member D (GPRC5D) Targeted Therapies Market Segmentation

• 9.1. Global G Protein-Coupled Receptor Family C Group 5 Member D (GPRC5D) Targeted Therapies Market, Segmentation By Therapy Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Monoclonal Antibodies, Bispecific Antibodies, Chimeric Antigen Receptor (CAR-T) Cell Therapies, Other Therapy Types
• 9.2. Global G Protein-Coupled Receptor Family C Group 5 Member D (GPRC5D) Targeted Therapies Market, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Multiple Myeloma, Solid Tumors, Other Indications
• 9.3. Global G Protein-Coupled Receptor Family C Group 5 Member D (GPRC5D) Targeted Therapies Market, Segmentation By Technology, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Precision Medicine Approaches, Molecular Targeted Therapy, Cancer Immunotherapy Platforms, Biopharmaceutical Drug Delivery Systems
• 9.4. Global G Protein-Coupled Receptor Family C Group 5 Member D (GPRC5D) Targeted Therapies Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Intravenous, Subcutaneous, Other Routes Of Administration
• 9.5. Global G Protein-Coupled Receptor Family C Group 5 Member D (GPRC5D) Targeted Therapies Market, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Hospitals, Specialty Clinics, Research Institutes, Other End-Users
• 9.6. Global G Protein-Coupled Receptor Family C Group 5 Member D (GPRC5D) Targeted Therapies Market, Sub-Segmentation Of Monoclonal Antibodies, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Fully Human Monoclonal Antibodies, Humanized Monoclonal Antibodies, Chimeric Monoclonal Antibodies, Murine Monoclonal Antibodies
• 9.7. Global G Protein-Coupled Receptor Family C Group 5 Member D (GPRC5D) Targeted Therapies Market, Sub-Segmentation Of Bispecific Antibodies, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Dual Targeting Bispecific Antibodies, Cross Linking Bispecific Antibodies, Immune Cell Engaging Bispecific Antibodies, Cytotoxic Bispecific Antibodies
• 9.8. Global G Protein-Coupled Receptor Family C Group 5 Member D (GPRC5D) Targeted Therapies Market, Sub-Segmentation Of Chimeric Antigen Receptor (CAR-T) Cell Therapies, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Autologous Car T Cell Therapies, Allogeneic Car T Cell Therapies, Next Generation Car T Cell Therapies, Gene Edited Car T Cell Therapies
• 9.9. Global G Protein-Coupled Receptor Family C Group 5 Member D (GPRC5D) Targeted Therapies Market, Sub-Segmentation Of Other Therapy Types, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Targeted Small Molecule Drugs, Receptor Specific Inhibitors, Injectable Biologics, Oral Targeted Therapeutics

10. G Protein-Coupled Receptor Family C Group 5 Member D (GPRC5D) Targeted Therapies Market Regional And Country Analysis

• 10.1. Global G Protein-Coupled Receptor Family C Group 5 Member D (GPRC5D) Targeted Therapies Market, Split By Region, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• 10.2. Global G Protein-Coupled Receptor Family C Group 5 Member D (GPRC5D) Targeted Therapies Market, Split By Country, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

11. Asia-Pacific G Protein-Coupled Receptor Family C Group 5 Member D (GPRC5D) Targeted Therapies Market

• 11.1. Asia-Pacific G Protein-Coupled Receptor Family C Group 5 Member D (GPRC5D) Targeted Therapies Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 11.2. Asia-Pacific G Protein-Coupled Receptor Family C Group 5 Member D (GPRC5D) Targeted Therapies Market, Segmentation By Therapy Type, Segmentation By Indication, Segmentation By Technology, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

12. China G Protein-Coupled Receptor Family C Group 5 Member D (GPRC5D) Targeted Therapies Market

• 12.1. China G Protein-Coupled Receptor Family C Group 5 Member D (GPRC5D) Targeted Therapies Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 12.2. China G Protein-Coupled Receptor Family C Group 5 Member D (GPRC5D) Targeted Therapies Market, Segmentation By Therapy Type, Segmentation By Indication, Segmentation By Technology, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

13. India G Protein-Coupled Receptor Family C Group 5 Member D (GPRC5D) Targeted Therapies Market

• 13.1. India G Protein-Coupled Receptor Family C Group 5 Member D (GPRC5D) Targeted Therapies Market, Segmentation By Therapy Type, Segmentation By Indication, Segmentation By Technology, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

14. Japan G Protein-Coupled Receptor Family C Group 5 Member D (GPRC5D) Targeted Therapies Market

• 14.1. Japan G Protein-Coupled Receptor Family C Group 5 Member D (GPRC5D) Targeted Therapies Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 14.2. Japan G Protein-Coupled Receptor Family C Group 5 Member D (GPRC5D) Targeted Therapies Market, Segmentation By Therapy Type, Segmentation By Indication, Segmentation By Technology, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

15. Australia G Protein-Coupled Receptor Family C Group 5 Member D (GPRC5D) Targeted Therapies Market

• 15.1. Australia G Protein-Coupled Receptor Family C Group 5 Member D (GPRC5D) Targeted Therapies Market, Segmentation By Therapy Type, Segmentation By Indication, Segmentation By Technology, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

16. Indonesia G Protein-Coupled Receptor Family C Group 5 Member D (GPRC5D) Targeted Therapies Market

• 16.1. Indonesia G Protein-Coupled Receptor Family C Group 5 Member D (GPRC5D) Targeted Therapies Market, Segmentation By Therapy Type, Segmentation By Indication, Segmentation By Technology, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

17. South Korea G Protein-Coupled Receptor Family C Group 5 Member D (GPRC5D) Targeted Therapies Market

• 17.1. South Korea G Protein-Coupled Receptor Family C Group 5 Member D (GPRC5D) Targeted Therapies Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 17.2. South Korea G Protein-Coupled Receptor Family C Group 5 Member D (GPRC5D) Targeted Therapies Market, Segmentation By Therapy Type, Segmentation By Indication, Segmentation By Technology, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

18. Taiwan G Protein-Coupled Receptor Family C Group 5 Member D (GPRC5D) Targeted Therapies Market

• 18.1. Taiwan G Protein-Coupled Receptor Family C Group 5 Member D (GPRC5D) Targeted Therapies Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 18.2. Taiwan G Protein-Coupled Receptor Family C Group 5 Member D (GPRC5D) Targeted Therapies Market, Segmentation By Therapy Type, Segmentation By Indication, Segmentation By Technology, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

19. South East Asia G Protein-Coupled Receptor Family C Group 5 Member D (GPRC5D) Targeted Therapies Market

• 19.1. South East Asia G Protein-Coupled Receptor Family C Group 5 Member D (GPRC5D) Targeted Therapies Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 19.2. South East Asia G Protein-Coupled Receptor Family C Group 5 Member D (GPRC5D) Targeted Therapies Market, Segmentation By Therapy Type, Segmentation By Indication, Segmentation By Technology, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

20. Western Europe G Protein-Coupled Receptor Family C Group 5 Member D (GPRC5D) Targeted Therapies Market

• 20.1. Western Europe G Protein-Coupled Receptor Family C Group 5 Member D (GPRC5D) Targeted Therapies Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 20.2. Western Europe G Protein-Coupled Receptor Family C Group 5 Member D (GPRC5D) Targeted Therapies Market, Segmentation By Therapy Type, Segmentation By Indication, Segmentation By Technology, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

21. UK G Protein-Coupled Receptor Family C Group 5 Member D (GPRC5D) Targeted Therapies Market

• 21.1. UK G Protein-Coupled Receptor Family C Group 5 Member D (GPRC5D) Targeted Therapies Market, Segmentation By Therapy Type, Segmentation By Indication, Segmentation By Technology, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

22. Germany G Protein-Coupled Receptor Family C Group 5 Member D (GPRC5D) Targeted Therapies Market

• 22.1. Germany G Protein-Coupled Receptor Family C Group 5 Member D (GPRC5D) Targeted Therapies Market, Segmentation By Therapy Type, Segmentation By Indication, Segmentation By Technology, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

23. France G Protein-Coupled Receptor Family C Group 5 Member D (GPRC5D) Targeted Therapies Market

• 23.1. France G Protein-Coupled Receptor Family C Group 5 Member D (GPRC5D) Targeted Therapies Market, Segmentation By Therapy Type, Segmentation By Indication, Segmentation By Technology, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

24. Italy G Protein-Coupled Receptor Family C Group 5 Member D (GPRC5D) Targeted Therapies Market

• 24.1. Italy G Protein-Coupled Receptor Family C Group 5 Member D (GPRC5D) Targeted Therapies Market, Segmentation By Therapy Type, Segmentation By Indication, Segmentation By Technology, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

25. Spain G Protein-Coupled Receptor Family C Group 5 Member D (GPRC5D) Targeted Therapies Market

• 25.1. Spain G Protein-Coupled Receptor Family C Group 5 Member D (GPRC5D) Targeted Therapies Market, Segmentation By Therapy Type, Segmentation By Indication, Segmentation By Technology, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

26. Eastern Europe G Protein-Coupled Receptor Family C Group 5 Member D (GPRC5D) Targeted Therapies Market

• 26.1. Eastern Europe G Protein-Coupled Receptor Family C Group 5 Member D (GPRC5D) Targeted Therapies Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 26.2. Eastern Europe G Protein-Coupled Receptor Family C Group 5 Member D (GPRC5D) Targeted Therapies Market, Segmentation By Therapy Type, Segmentation By Indication, Segmentation By Technology, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

27. Russia G Protein-Coupled Receptor Family C Group 5 Member D (GPRC5D) Targeted Therapies Market

• 27.1. Russia G Protein-Coupled Receptor Family C Group 5 Member D (GPRC5D) Targeted Therapies Market, Segmentation By Therapy Type, Segmentation By Indication, Segmentation By Technology, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

28. North America G Protein-Coupled Receptor Family C Group 5 Member D (GPRC5D) Targeted Therapies Market

• 28.1. North America G Protein-Coupled Receptor Family C Group 5 Member D (GPRC5D) Targeted Therapies Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 28.2. North America G Protein-Coupled Receptor Family C Group 5 Member D (GPRC5D) Targeted Therapies Market, Segmentation By Therapy Type, Segmentation By Indication, Segmentation By Technology, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

29. USA G Protein-Coupled Receptor Family C Group 5 Member D (GPRC5D) Targeted Therapies Market

• 29.1. USA G Protein-Coupled Receptor Family C Group 5 Member D (GPRC5D) Targeted Therapies Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 29.2. USA G Protein-Coupled Receptor Family C Group 5 Member D (GPRC5D) Targeted Therapies Market, Segmentation By Therapy Type, Segmentation By Indication, Segmentation By Technology, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

30. Canada G Protein-Coupled Receptor Family C Group 5 Member D (GPRC5D) Targeted Therapies Market

• 30.1. Canada G Protein-Coupled Receptor Family C Group 5 Member D (GPRC5D) Targeted Therapies Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 30.2. Canada G Protein-Coupled Receptor Family C Group 5 Member D (GPRC5D) Targeted Therapies Market, Segmentation By Therapy Type, Segmentation By Indication, Segmentation By Technology, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

31. South America G Protein-Coupled Receptor Family C Group 5 Member D (GPRC5D) Targeted Therapies Market

• 31.1. South America G Protein-Coupled Receptor Family C Group 5 Member D (GPRC5D) Targeted Therapies Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 31.2. South America G Protein-Coupled Receptor Family C Group 5 Member D (GPRC5D) Targeted Therapies Market, Segmentation By Therapy Type, Segmentation By Indication, Segmentation By Technology, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

32. Brazil G Protein-Coupled Receptor Family C Group 5 Member D (GPRC5D) Targeted Therapies Market

• 32.1. Brazil G Protein-Coupled Receptor Family C Group 5 Member D (GPRC5D) Targeted Therapies Market, Segmentation By Therapy Type, Segmentation By Indication, Segmentation By Technology, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

33. Middle East G Protein-Coupled Receptor Family C Group 5 Member D (GPRC5D) Targeted Therapies Market

• 33.1. Middle East G Protein-Coupled Receptor Family C Group 5 Member D (GPRC5D) Targeted Therapies Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 33.2. Middle East G Protein-Coupled Receptor Family C Group 5 Member D (GPRC5D) Targeted Therapies Market, Segmentation By Therapy Type, Segmentation By Indication, Segmentation By Technology, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

34. Africa G Protein-Coupled Receptor Family C Group 5 Member D (GPRC5D) Targeted Therapies Market

• 34.1. Africa G Protein-Coupled Receptor Family C Group 5 Member D (GPRC5D) Targeted Therapies Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 34.2. Africa G Protein-Coupled Receptor Family C Group 5 Member D (GPRC5D) Targeted Therapies Market, Segmentation By Therapy Type, Segmentation By Indication, Segmentation By Technology, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

35. G Protein-Coupled Receptor Family C Group 5 Member D (GPRC5D) Targeted Therapies Market Regulatory and Investment Landscape

36. G Protein-Coupled Receptor Family C Group 5 Member D (GPRC5D) Targeted Therapies Market Competitive Landscape And Company Profiles

• 36.1. G Protein-Coupled Receptor Family C Group 5 Member D (GPRC5D) Targeted Therapies Market Competitive Landscape And Market Share 2024
  • 36.1.1. Top 10 Companies (Ranked by revenue/share)
• 36.2. G Protein-Coupled Receptor Family C Group 5 Member D (GPRC5D) Targeted Therapies Market - Company Scoring Matrix
  • 36.2.1. Market Revenues
  • 36.2.2. Product Innovation Score
  • 36.2.3. Brand Recognition
• 36.3. G Protein-Coupled Receptor Family C Group 5 Member D (GPRC5D) Targeted Therapies Market Company Profiles
  • 36.3.1. Johnson And Johnson Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.2. F. Hoffmann-La Roche AG. Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.3. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.4. Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.5. AstraZeneca plc Overview, Products and Services, Strategy and Financial Analysis

37. G Protein-Coupled Receptor Family C Group 5 Member D (GPRC5D) Targeted Therapies Market Other Major And Innovative Companies

• Bristol Myers Squibb Company, Genmab A/S, Genentech Inc., Simcere Zaiming Biotechnology Co. Ltd., Innovent Biologics Inc., Essen Biotech Co. Ltd., Nanjing IASO Biotechnology Co. Ltd., CARsgen Therapeutics Holdings Limited, Oricell Therapeutics Co. Ltd., Integral Molecular Inc., Overland Therapeutics Inc., Qilu Pharmaceutical Co. Ltd., Leads Biolabs Ltd., Shanghai Yake Biotechnology Co. Ltd., Guangzhou Bio-gene Technology Co. Ltd.

38. Global G Protein-Coupled Receptor Family C Group 5 Member D (GPRC5D) Targeted Therapies Market Competitive Benchmarking And Dashboard

39. Upcoming Startups in the Market

40. Key Mergers And Acquisitions In The G Protein-Coupled Receptor Family C Group 5 Member D (GPRC5D) Targeted Therapies Market

41. G Protein-Coupled Receptor Family C Group 5 Member D (GPRC5D) Targeted Therapies Market High Potential Countries, Segments and Strategies

• 41.1 G Protein-Coupled Receptor Family C Group 5 Member D (GPRC5D) Targeted Therapies Market In 2030 - Countries Offering Most New Opportunities
• 41.2 G Protein-Coupled Receptor Family C Group 5 Member D (GPRC5D) Targeted Therapies Market In 2030 - Segments Offering Most New Opportunities
• 41.3 G Protein-Coupled Receptor Family C Group 5 Member D (GPRC5D) Targeted Therapies Market In 2030 - Growth Strategies
  • 41.3.1 Market Trend Based Strategies
  • 41.3.2 Competitor Strategies

42. Appendix

• 42.1. Abbreviations
• 42.2. Currencies
• 42.3. Historic And Forecast Inflation Rates
• 42.4. Research Inquiries
• 42.5. The Business Research Company
• 42.6. Copyright And Disclaimer